Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,232 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients.
Vidal C, García F, Gatell JM, Leal M, Clotet B, Pumarola T, Miró JM, Mallolas J, Ruiz L, Cruceta A, Tortajada C. Vidal C, et al. Among authors: garcia f. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Sep 1;19(1):55-60. doi: 10.1097/00042560-199809010-00009. J Acquir Immune Defic Syndr Hum Retrovirol. 1998. PMID: 9732070 Clinical Trial.
A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
García F, Romeu J, Grau I, Sambeat MA, Dalmau D, Knobel H, Gomez-Sirvent JL, Arrizabalaga J, Cruceta A, Clotet BG, Podzamczer D, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM. García F, et al. AIDS. 1999 Dec 3;13(17):2377-88. doi: 10.1097/00002030-199912030-00009. AIDS. 1999. PMID: 10597779 Clinical Trial.
Immunologic reconstitution after 1 year of highly active antiretroviral therapy, with or without protease inhibitors.
Plana M, Martínez C, García F, Maleno MJ, Barceló JJ, García A, Lejeune M, Vidal C, Cruceta A, Miró JM, Pumarola T, Gallart T, Gatell JM. Plana M, et al. Among authors: garcia a, garcia f. J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):429-34. doi: 10.1097/00126334-200204150-00001. J Acquir Immune Defic Syndr. 2002. PMID: 11981357 Clinical Trial.
Highly active antiretroviral therapy (HAART) modifies the incidence and outcome of visceral leishmaniasis in HIV-infected patients.
Tortajada C, Pérez-Cuevas B, Moreno A, Martínez E, Mallolas J, García F, Valls E, Miró JM, De Lazzari E, Gatell JM. Tortajada C, et al. Among authors: garcia f. J Acquir Immune Defic Syndr. 2002 Jul 1;30(3):364-6. doi: 10.1097/00126334-200207010-00015. J Acquir Immune Defic Syndr. 2002. PMID: 12131576 No abstract available.
The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals.
HIV-CAUSAL Collaboration; Ray M, Logan R, Sterne JA, Hernández-Díaz S, Robins JM, Sabin C, Bansi L, van Sighem A, de Wolf F, Costagliola D, Lanoy E, Bucher HC, von Wyl V, Esteve A, Casbona J, del Amo J, Moreno S, Justice A, Goulet J, Lodi S, Phillips A, Seng R, Meyer L, Pérez-Hoyos S, García de Olalla P, Hernán MA. HIV-CAUSAL Collaboration, et al. Among authors: garcia de olalla p. AIDS. 2010 Jan 2;24(1):123-37. doi: 10.1097/QAD.0b013e3283324283. AIDS. 2010. PMID: 19770621 Free PMC article.
3,232 results